Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2023. FOURTH-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts)...
Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that its subsidiary, Endo Health Solutions Inc. ("EHSI"), has agreed to resolve all issues regarding previously disclosed ...
Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A ...
Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada. XCOPRI is indicated as adjunctive therapy in the...
Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase clostridium histolyticum) were shared during the American...
Endo International plc (OTC: ENDPQ) ("Endo" or the "Company") today announced that it has taken an important step toward concluding its financial restructuring process by filing a proposed Plan of...
Endo International plc (OTC: ENDPQ) announced today the launch of its new branded video series, PD Pool Hall, which aims to educate people about Peyronie's disease (PD), a men's health condition that ...
Endo International plc (OTC: ENDPQ) announced today that five new presentations related to Peyronie's disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg)...
Endo International plc (OTC: ENDPQ) today reported financial results for the third-quarter ended September 30, 2023. THIRD-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three ...
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's...
Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the...
Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023. SECOND-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three...
Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in CURVE-PD (Clinical Understanding through Real-world data to Validate Effectiveness of treatments in...
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only...
Endo International plc (OTC: ENDPQ) and Premier, Inc. (NASDAQ: PINC) announced today that Endo's Par Sterile Products business will supply Pitocin® (oxytocin injection, USP) vials through Premier's...
Endo International plc (OTC: ENDPQ) announced today that new data from a Phase 1 study of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the ...
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's Noxafil® in the U....
Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI™ (cenobamate tablets) for adjunctive therapy in the...
Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for...
Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping dexlansoprazole 30 mg capsules, a generic version of Takeda's...
Endo International plc (OTC: ENDPQ) announced today that its Par Sterile Products business has begun shipping PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the ...
Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) in treating men with...
Endo International plc (OTC: ENDPQ) announced today that its subsidiary Endo Ventures Limited has executed an agreement with MAIA Pharmaceuticals, Inc. to distribute bivalirudin injection in a...
Endo International plc (OTC: ENDPQ) today reported financial results for the first-quarter ended March 31, 2023. FIRST-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three...
Endo International plc (OTC: ENDPQ) announced today that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. (collectively "Endo") have executed an agreement with Slayback Pharma LLC...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.